• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Nicoya Research

Nicoya Research

Intelligent Investment Research

  • Products & Services
    • Gold Stock Bull
    • High Growth Speculator
    • Crypto Corner
    • Income Insights
    • Mastermind Membership
  • News
    • Gold Price Prediction
    • Bitcoin Price Prediction
  • About
  • Help
  • Contact
  • My Account
  •  

Psychedelics are Medicine—and a Rising Investment Opportunity

January 6, 2021 By Jason Hamlin

For some, “psychedelic” and “medicine” are synonymous, and together, powerful. Investment into psychedelic drug companies is accelerating accordingly. Even before the 2020 election, when Oregon decriminalized all drugs including psychedelic substances and Washington D.C. decriminalized psilocybin mushrooms and entheogenic plants, the phrase “psychedelics industry” was increasingly being uttered by investors, researchers, and entrepreneurs alike. The increasing tendency of the FDA to approve psychedelic drug development is enabling psychedelic research to advance as, in tandem, the social stigma fades.

Psychedelics as Medicine

It would almost be easier to list which ailments psychedelics do not treat than to cover all the conditions for which, anecdotally at least, they can be effective. Paul Stamets describing to Joe Rogan how he stopped stuttering is a prime example of the surprising efficacy of psychoactive substances. Psychedelics, used medicinally, most commonly treat depression, anxiety, PTSD, addiction, and eating disorders. 

Psilocybin mushrooms and MDMA are the most studied psychedelic substances to date and each have proven effective at treating multiple maladies. Psilocybin is showing enough medicinal potential that the FDA has already on multiple occasions designated it as a Breakthrough Therapy. LSD, while already used recreationally on a widespread basis, is just starting to be studied by biotechnology companies for medicinal purposes. To highlight a few recent and ongoing studies:

  • Psilocybin can treat depression according to this 2020 study, and end-of-life anxiety according to this 2016 study, both conducted by Johns Hopkins researchers;
  • MDMA can treat PTSD according to this study by the Multidisciplinary Association for Psychedelic Studies;
  • LSD is being studied as a treatment for adult ADHD by the biotechnology company Mind Medicine in partnership with Maastricht University; and
  • LSD combined with MDMA is being researched by Mind Medicine to better understand the subjective effects of the combination.

Further off the beaten track, ayahuasca (also known as Grandmother) is a South American psychoactive plant medicine—actually two plants brewed together—known for its healing qualities. Investors take note: it is heavily attracting its own tourism (before the pandemic, anyway) in increasing volumes. Mescaline, DMT, ketamine, and iboga are each powerful psychoactive substances that deserve more attention and study than they have yet received.

Lead Actors in Psychedelic Medicine

The psychedelic medicine industry—one with vast commercial potential—is still emerging. The industry participants are still relatively few in number, with the most prominent including: 

  • COMPASS Pathways (NASDAQ: CMPS)—with a market cap approaching $1.6 billion—is by far the largest and also notable because it trades on the NASDAQ. COMPASS is researching the potential for psilocybin therapy to help people with treatment-resistant depression.
  • Mind Medicine (OTC: MMEDF)—market cap nearing $950 million—first studied ketamine and psilocybin mushrooms and has more recently expanded into researching the medicinal potential of each MDMA, DMT, and LSD.
  • Revive Therapeutics (OTC: RVVTF)—market cap north of $120 million—entered the psychedelics sector by acquiring Psilocin Pharma Corporation, which researches both natural and synthetically-derived psilocybin. Revive Therapeutics’ core business focus is cannabis.
  • Champignon Brands (OTC: SHRMF)—market cap nearing $54 million—distinguishes itself in the psychedelics marketplace by being a beverage company. It sells a product line of psilocybin mushroom-infused drinks, and has also been recently aquistive in effort to offer clinical ketamine treatments.
  • Mydecine Innovations Group (OTC: MYCOF)—market cap nearly $50 million—is studying the efficacy of psilocybin to treat veterans suffering from PTSD. Mydecine recently acquired the digital telehealth platform of the app MindLeap Health, which focuses on the psychedelics industry.

A list of other prominent industry participants is here. 

Psychedelics as an Investment Opportunity

The psychedelic medicines industry is predicted to grow rapidly. Between 2020 and 2027, an industry CAGR of 16.3 percent is expected, with the market value forecast to reach nearly $7 billion by 2027. The industry’s value in 2019 was just over $2 billion. Considering, too, the market potentials of other verticals such as psychedelics-focused media, lifestyle products, and consumer goods, the total addressable market for psychedelics is even greater than $7 billion. 

Global Mental Health Markets are Large & Underserved 

Source: MindMed

Treatment-Resistant Depression Affects 100 Million People Worldwide

Source: COMPASS Pathways

The psychedelics industry is still a relatively illiquid market, with few participants and even fewer publicly-traded companies—although the first psychedelics index already exists.

Lead Investors in Psychedelic Medicine 

If the universe of biotech companies working with psychoactive substances is small, then the number of investors with appetites for psychedelics companies is even smaller. 

Tabula Rasa Ventures and The Conscious Fund are each focused specifically on psychedelics, while better-known investors including Thiel Capital, New Enterprise Associates, Lightspeed Venture Partners, and Y Combinator have also invested in the sector.

Not Your Grandma’s Psychedelics

Gone are the days when psychedelics are synonymous with turning on, tuning in, and dropping out. Just like cannabis made its foray into the legal market as medicine, psychedelics are doing the same.

Social stigma is still attached to psychedelics and, like the stigma once associated with cannabis, is fading. Perhaps social acceptance of psychedelic substances, whether used recreationally or in therapeutic settings, will occur more slowly. But such acceptance is occurring nonetheless.

Amanda Feilding, Countess of Wemyss and founder of the Beckley Foundation, aptly summarizes the sentiment of many, stating, “After many decades, during which psychedelic research has been stifled by repressive drug laws and stigma, we are finally re-opening the doors to this fertile field. As the potential benefits of responsible use of psychedelics in therapeutic settings are uncovered, and the media awakens to these discoveries, a new enthusiasm for what psychedelics can offer both science and society is taking hold.” And investors are taking notice.

At Nicoya Research, we introduced subscribers to the first publicly-traded psychedelic medicine stock in early 2020 when it was around 40 cents per share. It has gone up nearly 10x since then. This week we added another psychedelic medicine stock to the High Growth Speculator Portfolio.

high growth speculator

Article by Nicoya Research contributor by Allie Grace

Filed Under: Cannabis, Stock Market Tagged With: mind medicine, mushroom stocks, psychedelic stocks

About Jason Hamlin

Jason Hamlin is the founder of Nicoya Research and has been publishing investment research at goldstockbull.com since 2006. His background is in data analytics for the world’s largest market research firm. Jason consulted to Fortune 500 companies around the globe, including Nestlé, Johnson & Johnson and Del Monte. Jason eventually left the corporate world and leveraged his analytical skills to trade stocks successfully full-time. Jason is a contrarian, cycles investor and student of Austrian economics. He is a regular speaker at investment conferences and proponent of sound money, limited government, decentralization of power and the non-aggression principle (NAP).

Related Posts

best stock democrats
Three Sectors Poised to Benefit From Democrats’ Sweep of Government
January 16, 2021
Tags: biden investments, biden stocks, democrats stocks, progressive stocks
Categories: Battery Metals, Cannabis, Predictions, Stock Market
2021 predictions gold bitcoin
7 Investment Predictions for 2021: Gold, Silver, Bitcoin, Battery Metals, Psychedelics, Gene Editing, and More
December 30, 2020
Tags: 2021 forecasts, 2021 investment trends, 2021 predictions, best stocks 2021, bitcoin price 2021, gold price 2021
Categories: Cannabis, Cryptocurrency, Mining Stocks, Predictions, Stock Market
stock crash 2020
Why the Stock Market is Slumping and What You Can Do
October 30, 2020
Tags: contested election investments, covid stocks, stock market crash
Categories: Geopolitical, Stock Market
Get the Nicoya Research 2019 Gold Stock Pick FREE guide!

Take Control of your Financial Future.

Sign up today and receive our FREE guide!

Footer

About Nicoya Research

Nicoya Research publishes financial research with the goal to help provide information and education for independent investors to profit in the markets. We study macroeconomic cycles, study analyst reports and go the extra mile to acquire the highest-quality information used to make successful investment decisions.
  • Email
  • Facebook
  • Twitter

Important Links

  • Home
  • About
  • Products & Services
  • News & Updates
  • Help
  • Contact
  • Affiliate Login
  • Affiliate Registration
  • Terms and Conditions
  • Privacy Policy

Our Publications

  • Gold Stock Bull
  • High Growth Speculator
  • Crypto Corner
  • Income Insights
  • Mastermind Membership

Latest News & Updates

Graphite: The Other Battery Metal

“Our battery should be called Nickel-Graphite." - … [Read More...] about Graphite: The Other Battery Metal

Top Silver Stock Pick for 2021

At Nicoya Research, we are expecting a breakout … [Read More...] about Top Silver Stock Pick for 2021

Read More News

Nicoya Research LLC is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. All ideas, opinions, and/or forecasts, expressed or implied herein, are for informational purposes only and should not be construed as a recommendation to invest, trade, and/or speculate in the markets. Any investments, trades, and/or speculations made in light of the ideas, opinions, and/or forecasts, expressed or implied herein, are committed at your own risk. The information on this site has been prepared without regard to any particular investor’s objectives, financial situation, and needs. Accordingly, investors should not act on any information on this site without obtaining specific advice from their financial advisor. Past performance is no guarantee of future results.

Copyright © 2021 Nicoya Research LLC · All Rights Reserved